Pabinafusp alfa
As of the edition of 20 October 2026, Pabinafusp alfa is a protein: marketed, first approved in 2021 (JP); acts on TFR2 and TFRC.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Protein
- First approved
- 23 March 2021 (JP)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- JCR Pharmaceuticals
- Registered trials
- 7, 0 stopped early
- Disease areas
- Inherited and neonatal; Nervous system; Nutrition and metabolism; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Pabinafusp alfa.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 2 | 1 | 0 |
| Phase 3 | 4 | 1 | 3 | 0 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| JCR Pharmaceuticals | Originator and Lead sponsor of trials | 2017 to now |